The Neuroform Atlas stent appears technically feasible and relatively safe for patients with symptomatic ICAS refractory to medical therapy, achieving high rates of functional independence. However, the evidence is limited by small, retrospective, single-arm studies and substantial heterogeneity. Large, randomized controlled trials are needed to define its role more clearly.
PETRY et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: